Perimenopause — a gradual transition in the years before menopause — is a period of big hormonal swings. It is one of the most significant and often misunderstood times in a woman’s life. And it’s a period when many women notice changes in their body composition, weight distribution, metabolism, and how their bodies respond to diet and exercise. These shifts affect many systems including hormones, metabolism, bone health, and cardiovascular function. The wide range of symptoms can feel unpredictable and frustrating. For many women, especially those struggling with perimenopausal weight gain and insulin resistance, GLP-1 receptor agonist medications (GLP-1s) have emerged as a promising treatment option. But how effective are they—and what does the research say?

In this article, we’ll break down:

• What GLP-1 drugs are
• How they work
• Why they might be relevant for perimenopausal women
• What the research shows so far, and what gaps remain

Understanding Perimenopause: A Metabolic Turning Point

Perimenopause typically begins in the 40s and can last 2-8+ years. It ends with menopause, defined as the cessation of a menses, and diagnosed only after 12 months without a period. During this transition, estrogen and progesterone fluctuate unevenly. This variability—not just low hormone levels—is what drives many symptoms. The hormonal shifts influence more than reproduction. They may also affect:

• Insulin sensitivity
• Fat distribution
• Muscle mass
• Appetite and satiety signals
• Sleep quality
• Stress response

As estrogen declines, the body tends to store more visceral fat even if caloric intake remains the same.¹ Muscle mass often decreases, lowering resting metabolic rate. Sleep disturbances and increased cortisol from stress can further contribute to weight gain and insulin resistance.

Many women describe not just perimenopausal weight gain, but also feeling as though the rules have changed, because they are doing the same things with very different results. Diet and exercise routines that once worked may no longer be as effective. This is where GLP-1 medications begin to enter the conversation—offering a sense of hope for women navigating these challenges.

What is a GLP-1 Medication? How do GLP-1s work?

“GLP-1” stands for glucagon-like peptide-1, which is a hormone produced in the gut in response to food to help control glucose metabolism and appetite signals in the brain. More specifically, this helps regulate:

• Appetite and satiety
• Food intake and cravings
• Insulin secretion in response to meals
• Rate of gastric emptying

GLP-1 receptor agonist medications mimic this hormone and act on the brain and gut to reduce hunger, slow digestion, and improve blood sugar management. They were originally developed to treat type 2 diabetes, but several, including semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound), are now approved for and widely prescribed for obesity and weight management.

GLP-1 drugs work by reducing appetite signals and increasing feelings of fullness. This dual action is why these medications can lead to significant weight loss. Trials such as the STEP² and SURMOUNT³ programs have consistently shown average weight loss of ~15–20% of baseline body weight compared to placebo over long-term treatment periods.

What the Research Says for Perimenopausal Women

Recent reviews show that GLP-1 medications are among the most effective drugs for weight loss across populations, including peri- and postmenopausal women.⁴ They are consistently associated with:

• Significant weight reduction 
• Decreased central adiposity 
• Potential improvements in cardiovascular markers 

Some emerging evidence even suggests they may help with vasomotor symptoms⁵ (like hot flashes), though this area requires further study.

However, there is an important caveat: research specific to perimenopausal women remains limited. Despite widespread use, this population is underrepresented in clinical trials, creating a knowledge gap around long-term safety and optimal use.

GLP-1s and Hormone Therapy

For perimenopausal women already using hormone therapy and considering adding GLP-1s, it’s important to understand how GLP-1s and hormone therapy may interact. Because GLP-1 medications slow gastric emptying, they can potentially affect the absorption of oral hormone therapy.⁶ Some research suggests this may reduce how effectively oral hormones are absorbed, although the degree of impact can vary depending on the specific medication.

It’s also worth noting that most of the available research on this interaction comes from studies on oral contraceptives—not hormone therapy and perimenopause specifically, where data remains limited. For this reason, women using oral hormone therapy should work closely with their healthcare provider to monitor symptoms, consider transdermal routes of application, and use hormone testing to monitor levels.

GLP-1s and Hormones: What They Don’t Do

While GLP-1 medications can significantly improve metabolic health, they do not directly correct hormonal changes driving perimenopausal symptoms. They are best understood as metabolic support and are not hormone therapy.

This distinction matters. A woman may lose weight on a GLP-1 medication but still experience:

• Poor sleep 
• Mood instability 
• Low libido 
• Hormonal migraines 

That’s where deeper hormonal insight becomes important.

GLP-1s and the DUTCH Test

While there is no perimenopause test, hormone testing can provide insight into the hormonal changes a woman is experiencing in midlife. A DUTCH test can provide something traditional serum testing often cannot: a broad picture of hormone levels and how they are processed in the body. 

The DUTCH Test and GLP-1s may serve different purposes, but they can be complementary:

• The DUTCH Test helps identify hormonal imbalances and guides personalized treatment (such as lifestyle changes, supplements, or hormone therapy). 
• GLP-1 medications help manage metabolic symptoms, particularly weight gain and blood sugar instability. 

Used together, they may help support a deeper understanding and a more complete treatment plan.

For example, a woman experiencing fatigue, belly weight gain, and poor sleep might discover through DUTCH testing that she has high cortisol at night and/or low progesterone. While GLP-1s may assist with weight management, addressing cortisol and progesterone imbalance is also key to long-term relief.

What does this mean? Can GLP-1 Medications be a metabolic tool for perimenopausal women?

Based on current evidence:

• GLP-1 medications work in adults with obesity — including women near or through menopause — to produce clinically meaningful weight loss. 
• There’s evidence of metabolic and cardiometabolic benefits, beyond just weight change.
• In perimenopausal or postmenopausal women, early data support efficacy regardless of reproductive stage, although research focused specifically on perimenopause remains limited. 

In practical terms, working with your clinician for treatments specific to you and your symptoms is important. If they include a GLP-1 medication, this should include:

• appropriate dosing
• gradual titration
• monitoring of side effects
• maintenance planning

to help you align treatment with your individual health goals.

However, GLP-1s drugs are not a cure-all. They don’t directly balance reproductive hormones, and their role in perimenopause is more supportive than corrective.

Shifts in Women’s Health: A Comprehensive Approach Matters

The rise of GLP-1 medications reflects a deeper issue: women’s health, especially in midlife, has been under-researched.

There are significant gaps in data on how treatments affect perimenopausal women specifically. GLP-1 drugs are widely used in this population, yet robust clinical guidance is still evolving. This provides opportunities for innovation and personalized care, but also a risk of overusing tools without strong evidence to support their benefits.

Plus, it is important it remember, perimenopause isn’t just about one hormone or one symptom—it’s a whole-body transition. The most effective strategies often combine:

• Hormone testing insight (like DUTCH testing)
• Hormone support (possibly hormone replacement)
• Metabolic support (potentially including GLP-1s) 
• Nutrition, sleep, exercise, and stress management 

Understanding your body’s unique patterns can make this phase feel far less chaotic—and far more manageable.

Final Thoughts

There’s no one-size-fits-all solution for perimenopause. Tools like the DUTCH Test can offer valuable information beyond just hormone levels, while GLP-1 medications may provide support for women navigating weight gain and metabolic changes. Used thoughtfully and under an experienced clinician’s guidance, these approaches may offer more personalized, informed care.

At the same time, the goal during perimenopause isn’t just weight loss—it’s building resilience for the years ahead. That means protecting muscle, bone density, cardiovascular health, cognitive function, and long-term metabolic stability. Whether through lifestyle changes, hormone therapy, GLP-1 medications, or a tailored combination of strategies, the focus should remain on overall health—not the number on the scale. With the right tools, medical guidance, and lifestyle support, midlife can be a powerful reset for long-term vitality.

To learn more about how the DUTCH Test can profoundly change the lives of your patients, become a DUTCH Provider today.

References:

1. Kapoor E, Collazo-Clavell ML, Faubion SS. Weight Gain in Women at Midlife: A Concise Review of the Pathophysiology and Strategies for Management. Mayo Clin Proc. 2017;92(10):1552-1558. doi:10.1016/j.mayocp.2017.08.004
2. Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med. 2022;134(sup1):5-17. doi:10.1080/00325481.2022.2147326
3. Hamza M, Papamargaritis D, Davies MJ. Tirzepatide for overweight and obesity management. Expert Opin Pharmacother. 2025;26(1):31-49. doi:10.1080/14656566.2024.2436595
4. Mikdachi H, Dunsmoor-Su R. GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence. Curr Opin Obstet Gynecol. 2025;37(2):97-101. doi:10.1097/GCO.0000000000001015
5. Graczyk NA, Bisschops J. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review. Cureus. 2026;18(1):e101693. Published 2026 Jan 16. doi:10.7759/cureus.101693
6. Min JS, Jo SJ, Lee S, et al. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. Drug Des Devel Ther. 2025;19:3509-3537. Published 2025 Apr 30. doi:10.2147/DDDT.S506957